| 000 | 01168 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250513031602.0 | ||
| 264 | 0 | _c19950504 | |
| 008 | 199505s 0 0 eng d | ||
| 022 | _a0959-8049 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMarty, M | |
| 245 | 0 | 0 |
_aThe optimal dose of glycosylated recombinant human granulocyte colony stimulating factor for use in clinical practice: a review. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _c1994 |
||
| 300 |
_aS20-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aErythroid Precursor Cells _xdrug effects |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aLenograstim |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aNeutrophils _xdrug effects |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aRecombinant Proteins _xadministration & dosage |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 30A Suppl 3 _gp. S20-5 |
|
| 999 |
_c7534528 _d7534528 |
||